Key facts
- This page summarizes Hongming Chen's Form 4 filing for Kala Pharmaceuticals, Inc. (KALA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Oct 2021, 20:06.
Hongming Chen - 26 Oct 2021 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)
- Reporting relationship
- CHIEF SCIENTIFIC OFFICER
- Issuer ticker
- KALA
- Reported as of
- 26 Oct 2021
- Net transaction value
- -$55,321
- SEC form
- 4
- Accepted by SEC
- 28 Oct 2021, 20:06:52 UTC
- Prior SEC filing
- 30 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric Trachtenberg, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Hongming Chen filed Form 4 for Kala Pharmaceuticals, Inc. (KALA) on 28 Oct 2021.
Change
- Previous filing in this sequence was filed on 30 Jun 2021.
- Current net transaction value: -$55,321.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KALA
transaction
Common Stock
Sale
- Transaction value
- $17,008
- Shares
- -9,449
- Change %
- -4%
- Price
- $1.80*
- Shares after
- 225,566
- Date
- 26 Oct 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F3
KALA
transaction
Common Stock
Sale
- Transaction value
- $38,313
- Shares
- -21,051
- Change %
- -9.3%
- Price
- $1.82*
- Shares after
- 204,515
- Date
- 27 Oct 2021
- Ownership
- Direct
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.
Footnote F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Footnote F3
Includes 61,166 unvested RSUs.
Footnote F4
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F5
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.84, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.